Login to Your Account

SuperGen Stock Drops; Dacogen Phase III Data Seen As Equivocal

By Kim Coghill

Friday, April 2, 2004

Confusion surrounding Phase III data for a myelodysplastic syndrome candidate named Dacogen caused SuperGen Inc.'s stock to dive, despite the firm's contention that the data are positive.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription